Waters Corp. Acquires Environmental Testing Firm
Waters Corp. in Milford has agreed to acquire all the outstanding stock of Environmental Resource Associates Inc. (ERA), an Arvada, CO-based firm for an undisclosed amount.
Waters Corp. in Milford has agreed to acquire all the outstanding stock of Environmental Resource Associates Inc. (ERA), an Arvada, CO-based firm for an undisclosed amount.
ERA, a privately-held company specializing in proficiency testing of environmental and pharmaceutical laboratories, has current annual revenues of approximately $17 million, and the acquisition is expected to be neutral to Waters Corp.'s earnings in 2007.
The transaction is expected to complete by the end of the year, and Waters vice president of Chemical Operations Ian King expects that the purchase will help the company to grow. "Environmental testing is a significant growth market for the company and the addition of ERA improves our access to this customer base."
Waters Corp. holds positions worldwide in three analytical technology markets: liquid chromatography, mass spectrometry and thermal analysis, accounting for $5 billion of the overall $20-$25 billion analytical instrument market.
Mitigating High Sample Volume Consumption in AAV Aggregate Analysis Using a Biozen™ dSEC-7 by SEC-FL
April 15th 2024This application note showcases a Biozen dSEC-7 SEC chemistry/fluorescence detector solution, offering reliable AAV aggregate analysis in under 10 minutes with as little as 0.5 µL of sample. Across four AAV serotypes, resolution between monomer and aggregates remains consistently high, emphasizing Biozen dSEC-7's efficiency and ability to maintain accurate detection at minimal injection volumes. Ideal for routine testing, this solution ensures precise measurement of a CQA with streamlined sample consumption.
Adeno-Associated Virus (AAV) Serotype Screen Using a Biozen™ dSEC-7 Size Exclusion Column
April 15th 2024With its 700 Å large pore silica particle and hydrophilic diol-type surface chemistry, Biozen dSEC-7 provides excellent resolution of monomer from dimer peaks in under 8 minutes across four different AAV serotypes. This capability is crucial for optimizing gene therapy biopharmaceuticals, ensuring thorough analytical scrutiny to select the most appropriate serotype(s) for enhanced therapeutic outcomes and immunogenic profiles.
